Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: a systematic review and meta-analysis.

Oncotarget · 2017 · PMC5620305 · PMID 28978165

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

did not reach statistical significanceP = 0.054so close (0.05 < p ≤ 0.1)

[ 15 ] found better severity and interference scores in the Brief Pain Inventory (BPI) in patients receiving zoledronic acid plus everolimus compared to those receiving everolimus alone, although the difference did not reach statistical significance ( P = 0.054 and 0.055, respectively), whereas no detectable effect was seen in the Functional Assessment of Cancer Therapy–Bone Pain scores ( P = 0.53).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.